All Metabolic disorders articles
-
NewsMetabolic vulnerabilities identified in rare Fibrolamellar liver cancer
Researchers have identified metabolic vulnerabilities in Fibrolamellar cancer, a rare liver malignancy affecting adolescents and young adults, using functional profiling and mass spectrometry. The findings suggest chemotherapy-resistant tumours may be susceptible to metabolism-targeted therapies.
-
NewsCholesterol trafficking disruption targets TP53-mutant cancers
Scientists have identified a mechanism to starve aggressive cancers by blocking cholesterol transport within tumour cells, offering a targeted approach for malignancies carrying TP53 mutations, present in half of all cancers.
-
NewsStudy reveals how GLP-1 drugs trigger weight loss in brain cells
NIH researchers have identified the intracellular signalling pathways through which semaglutide and other GLP-1 receptor agonists induce weight loss, revealing why patient responses vary and treatment effects plateau over time.
-
NewsGut-targeted drug proves effective against polycystic ovary syndrome in mice
Fudan University researchers report that fexaramine, an intestine-specific farnesoid X receptor agonist, improved metabolic and reproductive parameters in mouse models of polycystic ovary syndrome, supporting the gut–ovary axis hypothesis.
-
NewsMolecular switch discovery could lead to new bone disease treatments
A molecular switch that activates an alternative energy-burning pathway in brown fat has been identified by McGill University researchers, offering potential new approaches to treating bone disease and metabolic disorders through the TNAP enzyme’s glycerol pocket.
-
NewsHybrid molecule shows enhanced metabolic effects in obesity study
A novel hybrid molecule combining incretin therapy with targeted intracellular delivery of a PPAR agonist has demonstrated strong weight loss and glucose control compared to existing GLP-1/GIP therapies in preclinical studies.
-
NewsOsteoporosis drugs may slow progression of aortic aneurysms
Researchers at Nagoya University have identified clonal haematopoiesis as a driver of aortic aneurysm progression and demonstrated that FDA-approved osteoporosis therapies targeting the RANK/RANKL pathway can significantly slow disease progression in preclinical models.
-
NewsInsilico announces ISM6200 AI-designed drug candidate for ovarian cancer and cortisol disorders
Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.
-
NewsLactylation emerges as key driver of lung cancer resistance
New research from Shanghai Pulmonary Hospital outlines how lactate-driven lactylation acts as a metabolic switch controlling epigenetic regulation in lung cancer. The findings reveal self-reinforcing feedback loops that sustain drug resistance and suggest novel therapeutic strategies targeting the enzymes and pathways that maintain this process.
-
NewsFGF21 hormone targets hindbrain pathways to reverse obesity
New research reveals that FGF21, a hormone under investigation for obesity and metabolic dysfunction-associated steatohepatitis (MASH), works by signalling to the hindbrain rather than the hypothalamus. The discovery of this distinct neural circuit—which increases metabolic rate rather than simply suppressing appetite—could enable development of more precise therapies with fewer adverse effects than current FGF21 analogues.
-
NewsNew precision GLP-1 agonist could reduce side effects in patients
Researchers have developed a novel GLP-1 receptor agonist that preserves blood sugar control while reducing nausea and vomiting, offering a potential safer approach to treating diabetes and obesity.
-
NewsMemory-linked brain cells offer new obesity target for future therapies
Scientists have identified a brain circuit that connects contextual memory with appetite, advancing understanding of binge eating and obesity while highlighting a promising new target for drug discovery.
-
NewsNew SerpinB2 immune cell discovery could reverse type 2 diabetes
Researchers at the University of Pittsburgh School of Medicine have developed a new approach for tackling insulin resistance and type 2 diabetes by protecting beneficial immune cells in fat tissue.
-
NewsBeige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
-
NewsNew Type 2 diabetes drugs may improve insulin sensitivity
Scientists have used advanced computer modelling and lab techniques to design potential new diabetes drugs that improve insulin sensitivity.
-
NewsTRPM5 protein switch discovery could lead to new diabetes drugs
Northwestern University scientists have discovered a hidden ‘control switch’ in the TRPM5 protein, which helps regulate taste, blood sugar and gut health and could lead to new therapies for targeting diabetes and obesity.
-
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
-
NewsEstrone hormone linked to deadly breast cancer in obese women
A new analysis has identified the hormone estrone as a major driver of aggressive breast cancer in post-menopausal women with obesity, meaning that weight-loss drugs could help improve treatment outcomes.
-
NewsAI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
-
NewsBlood stem cell and islet cell transplant combo reverses type 1 diabetes
Stanford researchers have cured Type 1 diabetes in mice using a combination of blood stem cell and pancreatic islet cell transplants.